Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma

Keywords

Computer science

References

• Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 studyAurelio Desdentado Bonete — 2016
• The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, M.D., reviewed in the light of modern research.Helen C. Nauts, Walker E. Swift, Bradley L. Coley — 1946
• Immune escape of cancer cells with beta2‐microglobulin loss over the course of metastatic melanomaAna Belén Campo, Jon Amund Kyte, Javier Carretero — 2014
• Releasing the Brakes on Cancer Immunotherapy.Dan R. Littman — 2015
• The mechanism of action of BCG therapy for bladder cancer—a current perspectiveGil Redelman‐Sidi, Michael S. Glickman, Bernard H. Bochner — 2014
• Immune response following intravesical bacillus Calmette-Guerin instillations in superficial bladder cancer: a reviewJean Jacques Patard, F. Saint, Francesca Velotti — 1998
• Pembrolizumab for the treatment of non-small-cell lung cancer.Edward B. Garon, Naiyer A. Rizvi, Rina Hui — 2015
• Oncology meets immunology: the cancer-immunity cycle.Daniel S. Chen, Ira Mellman — 2013
• The prognostic significance of PD-L1 in bladder cancer.Yide Huang, Shudong Zhang, Cian M. McCrudden — 2015
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasionHaidong Dong, Scott E. Strome, Diva R. Salomão — 2002
• Continuous cultures of fused cells secreting antibody of predefined specificityGeorges Köhler, César Milstein — 1975
• New therapeutic challenges in advanced bladder cancer.Joaquim Bellmunt, Daniel P. Petrylak — 2012
• Cancer immunotherapy comes of ageIra Mellman, George Coukos, Glenn Dranoff — 2011
• Cancer immunoediting: from immunosurveillance to tumor escapeGavin P. Dunn, Allen T. Bruce, Hiroaki Ikeda — 2002
• INTRACAVITARY BACILLUS CALMETTE‐GUERIN IN THE TREATMENT OF SUPERFICIAL BLADDER TUMORSÁlvaro Morales, David Eidinger, Andrew W. Bruce — 1976
• The blockade of immune checkpoints in cancer immunotherapyDrew M. Pardoll — 2012
• Advances in targeting cell surface signalling molecules for immune modulationSheng Yao, Yuwen Zhu, Lieping Chen — 2013
• Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials.Richard Sylvester, Adrian P.M. van der Meijden, Donald L. Lamm — 2002
• Nivolumab and Ipilimumab versus Ipilimumab in Untreated MelanomaMichael A. Postow, Jason Chesney, Anna C. Pavlick — 2015
• Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.Christopher J. Sweeney, Bruce J. Roth, Fairooz F. Kabbinavar — 2006

Cited by

• Evolution of Cancer Pharmacological Treatments at the Turn of the Third MillenniumLuca Falzone, Salvatore Salomone, Massimo Libra — 2018
• Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient OutcomesSenthil Rajappa, Sanjiv Sharma, Kushal Prasad — 2019
• Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinomaIzak Faiena, Stephanie H. Astrow, David Elashoff — 2019
• Association of Melanoma-Associated Antigen-A and Program-death ligand 1 Expression and Clinical Outcomes in Urothelial CarcinomaI. Faiena — 2019
• Interobserver and Intraobserver agreement of PD-L1 scoring in Head and Neck Squamous Cell Carcinoma (HSCC), Urothelial Carcinoma (UC), and Breast Carcinoma (BC)Michelle R. Downes, Elzbieta Slodkowska, Nora Katabi — 2019
• Immune microenvironment and expression of PD-L1, PD-1, cancer testis antigen PRAME and MHC I in salivary duct carcinomaBin Xu, Achim A. Jungbluth, Denise Frosina — 2019
• The mechanism of anti-PD-L1 antibody efficacy against PD-L1 negative tumors identifies NK cells expressing PD-L1 as a cytolytic effectorWenjuan Dong, Xiaojin Wu, Shoubao Ma — 2019
• Molecular therapy with derivatives of amino benzoic acid inhibits tumor growth and metastasis in murine models of bladder cancer through inhibition of TNFα/NFΚB and iNOS/NO pathways.Julie Girouard, Denise Belgorosky, Jovane Hamelin-Morrissette — 2019
• Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non–muscle‐invasive bladder cancer (NMIBC): A cohort analysisMateusz Jobczyk, Konrad Stawiski, Wojciech Fendler — 2019
• Imunoterapia sistémica no carcinoma da bexiga avançado e metastizadoJuliana Pizarro Martins Gomes — 2019
• Serial assessment of circulating T lymphocyte phenotype and receptor repertoire during treatment of non-muscle invasive bladder cancer with adoptive T cell immunotherapy.Xiaoli Wang, Guoliang Qiao, Ni Jiang — 2020
• Immunotherapy in Bacillus Calmette-Guerin (BCG) unresponsive nonmuscle invasive bladder cancer.Lee A. Hugar, Scott M. Gilbert, Wade J. Sexton — 2020
• The Impact of Immune Checkpoint-Inhibitors Therapy in Urinary Bladder CancerAna Lúcia Silva, Pedro Abreu‐Mendes, Diana Martins — 2021
• Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer TherapyJi Woong Kim, Yea Bin Cho, Sukmook Lee — 2021
• The Ratio of IP10 to IL-8 in Plasma Reflects and Predicts the Response of Patients With Lung Cancer to Anti-PD-1 Immunotherapy Combined With ChemotherapyLiangliang Wu, Shengzhi Xie, Lingxiong Wang — 2021
• Antibody Therapy: From Diphtheria to Cancer, COVID-19, and BeyondDeepak Kumar, Sulgey Gauthami, Jagadeesh Bayry — 2021
• From Anti-PD-1/PD-L1 to CTLA-4 and to MUC1—Is the Better Response to Treatment in Smokers of Cancer Patients Drug Specific?Lishi Wang, Fengxia Liu, Jing Li — 2021
• A Generic Strategy to Generate Bifunctional Two-in-One Antibodies by Chicken ImmunizationJulia Harwardt, Jan P. Bogen, Stefania Carrara — 2022
• Looking for the Holy Grail—Drug Candidates for Glioblastoma Multiforme ChemotherapyBeata Pająk — 2022
• The Role of Immune Checkpoint Blockade in Acute Myeloid LeukemiaMargarida Silva, Diana Martins, Fernando Mendes — 2022

Related papers

No related papers recorded.